Drugs / 131I-chTNT-1/B MAb
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00677716 | Jul 2007 → Sep 2011 | glioblastoma | Peregrine Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131I-chTNT-1/B MAb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00677716 ↗ |
| Modality | Monoclonal antibody | “a targeted monoclonal antibody” NCT00677716 ↗ |
| Route | Other | “single interstitial infusion” NCT00677716 ↗ |